Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Latest updates in melanoma research

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 21.03.19
Views: 929
Rating:

Dr Alexander van Akkooi - The Netherlands Cancer Institute, Amsterdam, Netherlands

Dr Alexander van Akkooi speaks to ecancer at the 2019 EORTC Groups Annual Meeting (EGAM) about the latest research updates from the EORTC melanoma group.

Dr van Akkooi mentions a novel study that will examine the effects of BRAF- and MEK-directed therapy in combination with immunotherapy compared to immunotherapy alone. Additionally, this developing study will be aimed at BRAF-mutated, stage III, high-risk patients, or stage IV resected patients.

He also states a decline in the approval of melanoma drugs, along with inconsistencies with drug duration and therapy sequencing.

For the future, Dr van Akkooi and his group aim to initiate active trials for a range of melanoma patients, including those with advanced metastatic disease, brain metastases, ocular and UV melanoma.

Related videos

follow us

Tobacco Dependence e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation